Regular ArticlePrevention of Gallstone Formation in Morbidly Obese Patients Undergoing Rapid Weight Loss: Results of a Randomized Controlled Pilot Study
Presented at the 25th Annual Symposium of the Association of Veterans Administration Surgeons, Atlanta, Georgia, May 6–8, 2001
References (23)
- et al.
The epidemiology of gallbladder disease: observations in the Framingham study
J. Chronic Dis.
(1966) - et al.
A multi-center, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss
Am. J. Surg.
(1995) - et al.
Gallbladder mucin, arachidonic acid, and bile lipids in patients who develop gallstones during weight reduction
Gastroenterology
(1993) - et al.
Changes in gallbladder bile composition following gallstone formation and weight reduction
Gastroenterology
(1992) Pathogenesis of gallstones
Am. J. Surg.
(1993)Critical tables for calculating the cholesterol saturation of native bile
J. Lipid Res.
(1978)- et al.
A critical evaluation of real-time ultrasonography for the study of gallbladder volume and contraction
Gastroenterology
(1980) - et al.
The case for prophylactic cholecystectomy concomitant with gastric restriction for morbid obesity
Am. Surg.
(1988) - et al.
Gallbladder motility in cholesterol gallstone disease
Gastroenterology
(1990) - et al.
Drug-associated cholelithiasis: A case of sulindac stone formation and the incorporation of sulindac metabolites into the gallstones
Am. J. Gastroenterol.
(1999)
Gallstones in patients with morbid obesity: Relationship to body weight, weight loss and gallbladder bile cholesterol solubility
Int. J. Obesity
(1993)
Cited by (157)
Probiotics for gallstone prevention in patients with bariatric surgery: A prospective randomized trial
2022, Asian Journal of SurgeryThe impact of ursodeoxycholic acid on gallstone disease after bariatric surgery: a meta-analysis of randomized control trials
2022, Surgery for Obesity and Related DiseasesUrsodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial
2021, The Lancet Gastroenterology and HepatologySystematic review of management of gallbladder disease in patients undergoing minimally invasive bariatric surgery
2020, Surgery for Obesity and Related DiseasesCitation Excerpt :Several preventive measures in patients undergoing bariatric surgery have been proposed. One of the most studied medications to prevent cholelithiasis formation is UDCA, a secondary bile acid that increases cholesterol solubility in hepatic bile [29]. Several randomized trials have shown that UDCA decreases bile lithogenicity, concluding that UCDA can effectively prevent cholelithiasis and the risk of cholecystectomy after bariatric procedures [30–33].
Safety of concomitant cholecystectomy with laparoscopic sleeve gastrectomy and gastric bypass: a MBSAQIP analysis
2019, Surgery for Obesity and Related Diseases
- 1
To whom correspondence and reprint requests should be addressed at Division of Hepatobiliary Surgery and Liver Transplantation, Oxford House, Suite 801, Vanderbilt University Medical Center, Nashville, TN 37232-4753. Fax: (615) 343-1355. E-mail: [email protected].
Copyright © 2002 Elsevier Science (USA). All rights reserved.